Form 4: Heron Therapeutics EVP, CFO Ira Duarte Reports Stock Unit Vesting
SEC Form 4 Filing
Ira Duarte, EVP and CFO of Heron Therapeutics, reports the vesting of 3,875 common stock units on April 19, 2025, according to a Form 4 filing.
Summary
- On April 19, 2025, Ira Duarte, the Executive Vice President and Chief Financial Officer of Heron Therapeutics, Inc., had 3,875 common stock units vest.
- This transaction is reported in a Form 4 filing with the SEC.
- Following the transaction, Duarte directly owns 124,455 shares of common stock and 42,617 derivative securities (Restricted Stock Units).
Sentiment
Score: 5
Explanation: This is a routine filing related to stock unit vesting, which is neither particularly positive nor negative. It's a standard part of executive compensation.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The vesting of stock units may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/19/2024 | Date of grant for the restricted stock units, which vest in 16 equal quarterly installments beginning one quarter after this date. |
| 04/19/2025 | Date of transaction: 3,875 common stock units vested. |
| 04/22/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Heron Therapeutics, Ira Duarte, Stock Units, Vesting, HRTX, EVP, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.